Non‑Hormonal Contraception for Perimenopausal Women

Copper IUD (Cu‑T380A) – Efficacy and Duration

• The copper intrauterine device provides a typical‑use pregnancy rate of 0.8 % (0.8 pregnancies per 100 women) in the first year, making it the most effective non‑hormonal method for women around 47 years of age【1】【2】.
• Effectiveness is sustained over time, with the device approved for up to 10 years of continuous use, covering the interval to the average age of menopause【1】【2】.

Safety and Eligibility

• According to the U.S. CDC Medical Eligibility Criteria, the copper IUD is classified as Category 1 (no restrictions) for women ≥ 40 years, indicating no age‑related safety concerns【3】.

Insertion Protocol

• Insertion can be performed at any point in the menstrual cycle provided pregnancy can be reasonably excluded, eliminating the need to wait for the next menses【4】.
• A pelvic (bimanual) examination is required before insertion to assess uterine position and cavity depth【4】.
• Screening for gonorrhea and chlamydia may be done on the day of insertion, and if infection is detected, treatment can be administered without removing the IUD【1】.

Common Adverse Effects

• The most frequent reasons for discontinuation are increased menstrual bleeding and dysmenorrhea; these side effects should be discussed during counseling【5】.

Alternative Non‑Hormonal Methods – Effectiveness

Clinical Practice Recommendations (Pitfalls to Avoid)

• Do not require routine pre‑insertion screening such as cervical cytology, HIV testing, or laboratory panels for glucose, lipids, or hemoglobin; these are unnecessary for copper IUD placement【4】.
• Do not delay insertion while awaiting the next menstrual period; placement is acceptable anytime pregnancy can be excluded【4】.
• Do not prescribe prophylactic antibiotics at the time of insertion, as they do not reduce infection risk【3】.

Contraception in Women Over 40

Cardiovascular Risk Considerations

• The incidence of venous thromboembolism is higher among OCP users aged 45-49 years compared with younger users, though a direct interaction between hormonal contraception and increased age compared with baseline risk has not been consistently demonstrated 6
• The risk of myocardial infarction is higher among all OCP users than among non-users, though a trend of increased relative risk with increasing age has not been consistently demonstrated 6

Dosing Recommendations

• The U.S. Medical Eligibility Criteria for Contraceptive Use classifies combined hormonal contraceptives as Category 2 (benefits generally outweigh risks) for women ≥40 years 7

Alternative Contraceptive Options

• The American College of Obstetricians and Gynecologists recommends copper IUDs, levonorgestrel IUDs, contraceptive implants, and progestin-only pills as the most suitable birth control options for women over 40 due to their favorable safety profiles 7
• IUDs and progestin-only methods are classified as Category 1 (no restrictions) for women over 40 7

Duration of Contraceptive Use

• Contraceptive protection is still needed for women aged >44 years who want to avoid pregnancy 6
• Both the American College of Obstetricians and Gynecologists and the North American Menopause Society recommend that women continue contraceptive use until menopause or age 50-55 years 6
• The median age of menopause is approximately 51 years in North America but can vary from 40 to 60 years 6
• No reliable laboratory tests are available to confirm definitive loss of fertility; assessment of follicle-stimulating hormone levels may not be accurate 6

Common Pitfalls to Avoid

• Assuming fertility has ended before confirmed menopause (12 months without menses) can lead to unintended pregnancy 7
• Overlooking the increased risks of pregnancy in women of advanced reproductive age, including higher risks for maternal complications and fetal complications 6